Amgen Inc. has made a big deal about expanding into Japan and eventually building a stand-alone subsidiary there. Now, the biotech’s Japanese expansion strategy is paying off for at least one of its partners: Cytokinetics Inc.
The two companies announced June 12 that they have expanded an existing collaboration for the heart failure drug omecamtiv mecarbil...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?